What BrightHeart does
BrightHeart's B-Right platform analyzes fetal heart structures during prenatal ultrasound exams to help detect congenital heart defects, with the company reporting 96% sensitivity for severe defects. A second module, B-Right Views, tracks whether sonographers complete the full imaging protocol, which the company says cuts incomplete exams by 47%. The FDA-cleared, CE-marked system is designed to integrate with existing ultrasound machines and displays results on cart-side tablets during the scan, targeting ultrasound imaging centers, OB-GYN departments, and sonography practices.
BrightHeart is a healthcare tool on Falcoscan. AI platform that flags congenital heart defects in real time during prenatal ultrasounds. Falcoscan rates BrightHeart with an Opportunity score of 84/100, a Saturation score of 11/100, and a Wrapper-risk score of 9/100. Market signal: rising. BrightHeart is founded in 2022, currently at Series_a stage. Pricing: Paid.